Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey.

Q1 Medicine
Asia Pacific Family Medicine Pub Date : 2015-04-23 eCollection Date: 2015-01-01 DOI:10.1186/s12930-015-0020-9
Sam Lim, David Chi-Leung Lam, Abdul Razak Muttalif, Faisal Yunus, Somkiat Wongtim, Le Thi Tuyet Lan, Vikram Shetty, Romeo Chu, Jinping Zheng, Diahn-Warng Perng, Teresita de Guia
{"title":"Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey.","authors":"Sam Lim, David Chi-Leung Lam, Abdul Razak Muttalif, Faisal Yunus, Somkiat Wongtim, Le Thi Tuyet Lan, Vikram Shetty, Romeo Chu, Jinping Zheng, Diahn-Warng Perng, Teresita de Guia","doi":"10.1186/s12930-015-0020-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a clinical syndrome encompassing a group of chronic, progressive, and debilitating respiratory conditions, that are characterized by incompletely reversible airflow limitation. Within the Asia-Pacific region, prevalence estimates have been derived using various protocols and study methods, and there is little data on the impact of COPD exacerbations. This study aimed to provide a comprehensive picture of the current prevalence and burden of COPD in this region.</p><p><strong>Methods: </strong>A population-based survey was conducted in nine Asia-Pacific territories between 01 February 2012 and 16 May 2012. Overall, 112,330 households were screened to identify eligible subjects (aged ≥40 years, with a physician diagnosis of COPD, chronic bronchitis or emphysema, or with identifiable symptoms of chronic bronchitis). Out of a sample of 69,279 individuals aged ≥40 years, 4,289 subjects with COPD were identified. Data were collected via face-to-face interviews or by fixed-line telephone, using a structured questionnaire. A total of 1,841 completed questionnaires were analyzed.</p><p><strong>Results: </strong>The overall estimated COPD prevalence was 6.2%, with 19.1% of subjects having severe COPD. In the 12 months prior to the survey, nearly half of all subjects (46%) had experienced exacerbations, and 19% had been hospitalized as a result of their condition. When subjects were asked about the impact of their condition on employment, 23% said their condition kept them from working, and 42% felt that their condition limited their ability to work or their activities. Of those who reported taking prescription drugs, 20% did not know the name of the drugs they were taking. Prescription of oral corticosteroids was common, with 44% of subjects having used these during the previous year to manage their respiratory symptoms; in contrast, inhaler use was low (25%). Only 37% of subjects had taken a lung function test, and the majority (89%) of those tested did not know their test results.</p><p><strong>Conclusions: </strong>Across the Asia-Pacific territories surveyed, the prevalence of COPD is high, indicating a substantial socioeconomic burden. Our findings suggest that there is considerable room for improvement in the management of COPD, and highlight a need to enhance patient and physician education in the region.</p>","PeriodicalId":39050,"journal":{"name":"Asia Pacific Family Medicine","volume":"14 1","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2015-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416253/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Family Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12930-015-0020-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a clinical syndrome encompassing a group of chronic, progressive, and debilitating respiratory conditions, that are characterized by incompletely reversible airflow limitation. Within the Asia-Pacific region, prevalence estimates have been derived using various protocols and study methods, and there is little data on the impact of COPD exacerbations. This study aimed to provide a comprehensive picture of the current prevalence and burden of COPD in this region.

Methods: A population-based survey was conducted in nine Asia-Pacific territories between 01 February 2012 and 16 May 2012. Overall, 112,330 households were screened to identify eligible subjects (aged ≥40 years, with a physician diagnosis of COPD, chronic bronchitis or emphysema, or with identifiable symptoms of chronic bronchitis). Out of a sample of 69,279 individuals aged ≥40 years, 4,289 subjects with COPD were identified. Data were collected via face-to-face interviews or by fixed-line telephone, using a structured questionnaire. A total of 1,841 completed questionnaires were analyzed.

Results: The overall estimated COPD prevalence was 6.2%, with 19.1% of subjects having severe COPD. In the 12 months prior to the survey, nearly half of all subjects (46%) had experienced exacerbations, and 19% had been hospitalized as a result of their condition. When subjects were asked about the impact of their condition on employment, 23% said their condition kept them from working, and 42% felt that their condition limited their ability to work or their activities. Of those who reported taking prescription drugs, 20% did not know the name of the drugs they were taking. Prescription of oral corticosteroids was common, with 44% of subjects having used these during the previous year to manage their respiratory symptoms; in contrast, inhaler use was low (25%). Only 37% of subjects had taken a lung function test, and the majority (89%) of those tested did not know their test results.

Conclusions: Across the Asia-Pacific territories surveyed, the prevalence of COPD is high, indicating a substantial socioeconomic burden. Our findings suggest that there is considerable room for improvement in the management of COPD, and highlight a need to enhance patient and physician education in the region.

Abstract Image

Abstract Image

Abstract Image

亚太地区慢性阻塞性肺病 (COPD) 的影响:EPIC 亚洲人口调查。
背景:慢性阻塞性肺疾病(COPD)是一种临床综合征,包括一组慢性、进行性和使人衰弱的呼吸系统疾病,其特征是不完全可逆的气流受限。在亚太地区,流行率的估算采用了不同的方案和研究方法,而有关慢性阻塞性肺病恶化影响的数据却很少。本研究旨在全面了解该地区慢性阻塞性肺病的患病率和负担现状:方法:2012 年 2 月 1 日至 2012 年 5 月 16 日期间,在九个亚太地区开展了一项基于人口的调查。总共筛选了 112,330 个家庭,以确定符合条件的受试者(年龄≥40 岁,经医生诊断患有慢性阻塞性肺病、慢性支气管炎或肺气肿,或有可识别的慢性支气管炎症状)。在 69,279 名年龄≥40 岁的样本中,确定了 4,289 名慢性阻塞性肺病患者。数据是通过面对面访谈或固定电话,使用结构化问卷收集的。共分析了 1,841 份完成的问卷:据估计,慢性阻塞性肺病的总体患病率为 6.2%,其中 19.1%的受访者患有严重的慢性阻塞性肺病。在调查前的 12 个月中,近一半的受试者(46%)的病情曾加重,19% 的受试者因病情加重而住院治疗。当被问及病情对就业的影响时,23% 的受试者说他们的病情让他们无法工作,42% 的受试者认为他们的病情限制了他们的工作或活动能力。在报告服用处方药的受试者中,20% 的人不知道所服用药物的名称。开具口服皮质类固醇处方的情况很普遍,44%的受试者在过去一年中曾使用此类药物来控制呼吸道症状;相比之下,吸入器的使用率较低(25%)。只有 37% 的受试者进行过肺功能测试,大多数受试者(89%)不知道自己的测试结果:在接受调查的亚太地区,慢性阻塞性肺病的发病率很高,这表明慢性阻塞性肺病给社会经济造成了沉重负担。我们的研究结果表明,慢性阻塞性肺病的管理还有很大的改进空间,并强调了在该地区加强患者和医生教育的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Asia Pacific Family Medicine
Asia Pacific Family Medicine Medicine-Family Practice
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信